Mollie Barnes

Brain tumors can present many different symptoms. A Keck Medicine of USC neurosurgeon explains when you should see a doctor.

Not all licensing deals are successful. Here, BioSpace examines a few noteworthy assets that Big Pharma returned in the last 12 months.

The size of the global immunology market is projected to nearly double by 2032 to a quarter of a trillion dollars. Here are this year’s standout deals in the space.

For rare cancers such as sarcoma, it is important to get treatment at a center with multiple types of specialists.

USC Sarcoma Program specialists explain types of sarcomas, symptoms of a sarcoma and new treatments for these rare cancers.

Losing weight can be difficult. Seeing a specialist can help determine if weight loss drugs are right for you.

In light of the massive revenues pharma companies are generating in the obesity space and the pressure many companies are under from looming loss of exclusivity (LOE) on top drugs, analysts don’t see M&A activity slowing down anytime soon. Here are some companies to watch for.

After the rise of weight loss injections like Wegovy and Zepbound, a Keck Medicine of USC doctor talks about what’s next in obesity treatment.

The American Society of Clinical Oncology annual meeting kicks off today in Chicago, with several companies releasing highly anticipated abstracts ahead of time. Here are some that caught our attention.

Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients with lung cancer, experts told BioSpace.

Adeno-associated viruses, or AAVs, are the workhorse vector of gene therapies. With the American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting set to kick off this week, scientists and pharmaceutical executives are gearing up to discuss the latest in capsid development to support a new generation of gene therapies.

After five years at USC, four chief residents prepare to move on to fellowships and attending positions

It’s the perfect destination for travelers who love cozy small-town vibes, as well as those who seek extreme outdoor adventures.

AbbVie has so far defended its majority market share among biologics for rheumatoid arthritis despite the loss of exclusivity for its flagship drug Humira (adalimumab). But for the first time since Humira biosimilars appeared last summer, the company’s dominance might be slipping as insurers change coverage policies.

Nummular eczema and ringworm look very similar, and it can be very difficult for the average person to distinguish it. “Even a general doctor without an expertise in dermatology can have a hard time spotting the subtle differences,” said dermatologist Dr. Benjamin Ungar.